Matching articles for "lecanemab"

Donanemab (Kisunla) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • August 19, 2024;  (Issue 1709)
Donanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer's disease (AD). The label states that the drug should only be...
Donanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed monoclonal antibody, has been approved by the FDA for treatment of Alzheimer's disease (AD). The label states that the drug should only be started in patients with mild cognitive impairment (MCI) or mild dementia. Donanemab is the third IV amyloid beta-directed monoclonal antibody to be marketed in the US. Lecanemab (Leqembi – Biogen/Eisai) was approved by the FDA in 2023 for the same indication as donanemab. Aducanumab (Aduhelm – Lilly) was granted accelerated approval in 2021, but it was withdrawn from the market earlier this year for commercial reasons.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):129-31 | Show Full IntroductionHide Full Introduction

Table: Amyloid-Directed Antibodies for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • August 5, 2024;  (Issue 1708)
...
View the Table: Amyloid-Directed Antibodies for Alzheimer's Disease
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-2 | Show Full IntroductionHide Full Introduction

Lecanemab (Leqembi) Granted Full Approval for Early Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • August 21, 2023;  (Issue 1683)
Lecanemab-irmb (Leqembi – Eisai/Biogen), the IV amyloid-directed monoclonal antibody that received accelerated approval from the FDA in January 2023 for treatment of early Alzheimer's disease, has...
Lecanemab-irmb (Leqembi – Eisai/Biogen), the IV amyloid-directed monoclonal antibody that received accelerated approval from the FDA in January 2023 for treatment of early Alzheimer's disease, has now received full approval from the FDA based on a trial showing that it slowed cognitive and functional decline in patients with mild cognitive impairment (MCI) or mild Alzheimer's disease dementia and confirmed presence of brain amyloid. The IV amyloid-directed monoclonal antibody aducanumab (Aduhelm) has received only an accelerated FDA-approval for the same indication.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):129-30 | Show Full IntroductionHide Full Introduction

Lecanemab (Leqembi) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • February 6, 2023;  (Issue 1669)
Lecanemab-irmb (Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that...
Lecanemab-irmb (Leqembi – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The label states that treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild dementia, the population in which the drug was initiated in clinical trials. Lecanemab is the second IV amyloid-beta directed monoclonal antibody to be approved for this indication; aducanumab (Aduhelm) was approved in 2021 and has the same restrictions on treatment initiation.
Med Lett Drugs Ther. 2023 Feb 6;65(1669):17-8 | Show Full IntroductionHide Full Introduction

Comparison Table: Drugs for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • August 22, 2022;  (Issue 1657)
...
View the Comparison Table: Drugs for Alzheimer's Disease
Med Lett Drugs Ther. 2022 Aug 22;64(1657):e136-7 | Show Full IntroductionHide Full Introduction